Cumberland Pharmaceuticals Inc (CPIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $88.16M
Last updated: Nov 17, 2026 at 4:41 PM ET
Cumberland Pharmaceuticals Inc (CPIX) Statistics
Cumberland Pharmaceuticals (CPIX) has a market cap of $88.16M and an enterprise value of $7.58M. It kept 273.70% of revenue as net income over the last 12 months. Its dividend yield is 25.86%.
Total Valuation
Enterprise value is 91.41% below the market cap, as cash exceeds debt.
| Market Cap | $88.16M |
|---|---|
| Enterprise Value | $7.58M |
| Latest price (Nov 17, 2026) | $5.80 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Jul 23, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Last Ex-Dividend Date | Jul 23, 2026 |
| Last Payment Date | Jul 31, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.5x and 1.2x. Its year-end P/S ranged from 0.6x to 3.2x from 2016 to 2025.
| P/S Ratio | 3.5x |
|---|---|
| P/B Ratio | 1.2x |
| P/TBV Ratio | 1.2x |
Enterprise Valuation
| EV / Earnings | 0.1x |
|---|---|
| EV / Sales | 0.3x |
Price Statistics
The stock is up 232.30% over 52 weeks and trades 11.99% below its 50-day average.
| Beta (1Y) | 0.55 |
|---|---|
| 52-Week Change | +232.30% |
| 1-Month Change | -13.43% |
| 3-Month Change | -24.18% |
| 6-Month Change | +29.61% |
| 5-Year Change | +74.35% |
| 10-Year Change | -1.26% |
| Total Return (1Y) | +404.18% |
| Total Return (3Y CAGR) | +61.31% |
| Total Return (5Y CAGR) | +22.44% |
| Return vs SPY (1Y) | +244.36% |
| Max Drawdown (1Y) | -52.95% |
| Max Drawdown (3Y) | -71.93% |
| Sharpe Ratio (1Y) | 1.10 |
| Correlation with SPY (1Y) | 0.07 |
| 50-Day Average | $6.59 |
| 200-Day Average | $5.08 |
| 52-Week Range | $1.15 to $9.28 |
| RSI (14 Days) | 49.1 |
| Average Volume (20 Days) | 238.81K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.05x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.05x |
|---|---|
| Quick Ratio | 3.04x |
| Debt / Equity | 0.00x |
| Interest Coverage | -47.02x |
Returns and Efficiency
Return on equity is 94.87% over the last 12 months, against a 5-year average of -17.02%.
| Return on Equity (ROE) | 94.87% |
|---|---|
| Return on Assets (ROA) | 60.46% |
| ROE (5Y Average) | -17.02% |
| ROA (5Y Average) | -6.07% |
| ROIC (5Y Average) | -13.13% |
| Asset Turnover | 0.28x |
| Inventory Turnover | 139.48x |
| Receivables Turnover | 1.94x |
| Cash Conversion Cycle | -1385 days |
Scores
CPIX has an Altman Z-Score of 2.19, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.19 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $25.13M over the last 12 months is up 10.71% from the 12 months before.
| Revenue | $25.13M |
|---|---|
| Revenue Growth (YoY) | +10.71% |
| Gross Profit | $20.96M |
| Operating Income | -$9.60M |
| Pretax Income | -$8.75M |
| Net Income | $68.79M |
| EBITDA | -$6.42M |
| Reported EPS (TTM) | -$0.58 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 63.73% of the $113.78M in total assets.
| Cash and Equivalents | $80.58M |
|---|---|
| Total Debt | $0 |
| Net Cash | $80.58M |
| Net Cash Per Share | $5.38 |
| Working Capital | $70.23M |
| Shareholder Equity | $72.51M |
| Book Value Per Share | $4.84 |
| Tangible Book Value | $72.47M |
| Tangible Book Per Share | $4.83 |
| Total Assets | $113.78M |
| Total Liabilities | $41.60M |
Balance sheet as of Sep 30, 2026.
Margins
The operating margin is -38.19%, against a 5-year average of -16.47%.
| Gross Margin | 83.39% |
|---|---|
| Operating Margin | -38.19% |
| Pretax Margin | -34.81% |
| Net Margin | 273.70% |
| EBITDA Margin | -25.54% |
| Gross Margin (5Y Average) | 81.22% |
| Operating Margin (5Y Average) | -16.47% |
| Net Margin (5Y Average) | -12.58% |
Growth
Revenue grew 1.95% a year over 3 years.
| Revenue Growth (3Y CAGR) | +1.95% |
|---|---|
| Revenue Growth (5Y CAGR) | +3.52% |
| FCF Growth (3Y CAGR) | -16.66% |
| FCF Growth (5Y CAGR) | -1.73% |
| Book Value Per Share Growth (2Y CAGR) | -10.79% |
| Tangible Book Per Share Growth (2Y CAGR) | +96.62% |
Dividends and Yields
CPIX pays out 32.69% of earnings as dividends.
| Dividend Per Share (Annual) | $1.50 |
|---|---|
| Dividend Yield | 25.86% |
| Payout Ratio | 32.69% |
Peer Position
Against 6 similar companies, CPIX has the highest P/S.
P/S RatioPeer median 1.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -1.48%
| P/S Ratio | 3.5x vs 1.0x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.71% vs -1.48% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CPIX
What is CPIX's market cap?
Cumberland Pharmaceuticals has a market cap of $88.16M. Its enterprise value, which adds debt and subtracts cash, is $7.58M.
How many shares of CPIX are outstanding?
Cumberland Pharmaceuticals has 14.99M shares outstanding. The count is up 0.21% from a year earlier.
Does CPIX pay a dividend?
Yes. Cumberland Pharmaceuticals pays $1.50 a share a year, a dividend yield of 25.86%.
How much debt does CPIX have?
Cumberland Pharmaceuticals has $0 of total debt and $80.58M of cash and equivalents, a net cash position of $80.58M.
CPIX pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors